Clinical Trials Logo

Cetuximab clinical trials

View clinical trials related to Cetuximab.

Filter by:
  • None
  • Page 1

NCT ID: NCT06118047 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Crisaborole Ointment for Skin Toxicity Induced by Cetuximab

COSTIC
Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, phase II clinical trial that will enroll metastatic colorectal cancer patients with Cetuximab-Related Skin Toxicity, who will receive crisaborole ointment twice daily.

NCT ID: NCT06101394 Recruiting - Lung Cancer Clinical Trials

Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules

RECOGNISE
Start date: January 2024
Phase: Phase 2
Study type: Interventional

To date, lung resection and lymphadenectomy remain the best curative option in patients with early-stage non-small cell lung cancer. Moreover, cancer screening programs have led to a frequent diagnoses of indeterminate lung lesions, many of which require surgical biopsy for diagnosis and intervention. Additionally, pre-operative imaging assessment frequently underestimates lymph-node involvement. Finally, the increase in the utilization of minimally invasive procedures remains mandatory. The aim of our project is to verify if Cetuximab-IRDye800 could detect cancer nodules and lymph node metastases during minimally invasive thoracic surgery. A result favoring the use of Cetuximab-IRDye800 would permit the use of a minimally invasive approach to a more significant number of patients, which are presently operable only by a traditional "open" approach. Consequentially, it would lead to an improvement in surgical outcomes, a reduction of costs, and an enhanced patient quality of life. In addition, a result favoring Cetuximab-IRDye800 could consent to correctly remove mislead metastatic lymph nodes (i.e., unexpected lymph-nodes metastasis) and neoplastic localization unidentified at pre-operative diagnostic assessments. It would lead to more accurate cancer staging, and a tailored post-operative treatment. Finally, the investigators expect to validate using Cetuximab-IRDye800 as an optimal tracker that can be easily applied intraoperatively during minimally invasive surgical procedures.

NCT ID: NCT05022030 Recruiting - Colo-rectal Cancer Clinical Trials

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

CAPCET
Start date: July 21, 2021
Phase: Phase 2
Study type: Interventional

This prospective, randomized, phase 2 study is conducted to evaluate the efficacy and safety of first line mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided CRC patients with wild-type RAS and BRAF genes.

NCT ID: NCT04923620 Recruiting - Rectal Cancer Clinical Trials

Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy

Start date: October 20, 2021
Phase:
Study type: Observational [Patient Registry]

Prospectively Investigate the effectiveness and safety of neoadjuvant cetuximab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS wild-type locally advanced rectal cancer

NCT ID: NCT04509635 Not yet recruiting - Colorectal Cancer Clinical Trials

Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis

Start date: September 1, 2020
Phase: Phase 3
Study type: Interventional

For patients with unresectable colorectal cancer liver metastases, preclinical studies have shown that after the resistance of cetuximab, the treatment sensitivity can be restored by stopping cetuximab for a period of time. This is called the cetuximab re-challenge. And the circulating tumor DNA (ctDNA) test is reported a biomarker for the efficacy of cetuximab rechallenge. However, there is still no randomized controlled trial for verification. This study aims at patients after the first-line treatment of cetuximab has progressed. After the second-line non-cetuximab treatment has progressed, the effects of re-application of combined with cetuximab and chemotherapy alone are compared to verify the re-challenge effect.

NCT ID: NCT04136600 Recruiting - Gastric Cancer Clinical Trials

EGFR Monoclonal Antibody for Advanced Gastric Cancer

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

This study is intended to evaluate efficacy and safety of EGFR monoclonal antibody (Cetuximab/Nimotuzumab) in combination with a chemotherapy in gastric cancer patients with EGFR amplification.